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The molecular basis of the broad substrate recognition and the transport of substrates by Cdr1p, a
major drug efflux protein of Candida albicans, is not well understood. To investigate the role of
transmembrane domains and nucleotide-binding domains (NBDs) of Cdr1p in drug transport,
two sets of protein chimeras were constructed: one set between homologous regions of Cdr1p and
the non-drug transporter Cdr3p, and another set consisting of Cdr1p variants comprising either
two N- or two C-terminal NBDs of Cdr1p. The replacement of either the N- or the C-terminal half of
Cdr1p by the homologous segments of Cdr3p resulted in non-functional recombinant strains
expressing chimeric proteins. The results suggest that the chimeric protein could not reach the
plasma membrane, probably because of misfolding and subsequent cellular trafficking problems,
or the rapid degradation of the chimeras. As an exception, the replacement of transmembrane
segment 12 (TMS12) of Cdr1p by the corresponding region of Cdr3p resulted in a functional
chimera which displayed unaltered affinity for all the tested substrates. The variant protein
comprising either two N-terminal or two C-terminal NBDs of Cdr1p also resulted in non-functional
recombinant strains. However, the N-terminal NBD variant, which also showed poor cell surface
localization, could be rescued to cell surface, if cells were grown in the presence of drug substrates.
The rescued chimera remained non-functional, as was evident from impaired ATPase and efflux
activities. Taken together, the results suggest that the two NBDs of Cdr1p are asymmetric and
non-exchangeable and that the drug efflux by Cdr1p involves complex interactions between the two
halves of the protein.
INTRODUCTION
Among ABC transporters, Cdr1p has been shown to play a
key role in azole resistance in Candida albicans as deduced
from its high level of expression in several azole-resistant
clinical isolates recovered from patients receiving long-term
antifungal therapy (Sanglard et al., 1995). Additionally, a
high level of expression of Cdr1p invariably contributes to
an increased efflux of fluconazole, thus corroborating its
direct involvement in drug efflux (Sanglard et al., 1995;White
et al., 1998). Cdr1p thus has not only acquired significant
clinical importance but is considered an important player in
any design of strategies to combat antifungal resistance.
TheCDR1 gene encodes an integral plasmamembrane (PM)
protein of 1501 amino acids, with a predicted molecular
mass of 169?9 kDa. The topology of Cdr1p exhibits typical
characteristic features of an ABC transporter: two highly
hydrophobic transmembrane domains (TMDs) and two
cytoplasmically localized nucleotide-binding domains
(NBDs). Each TMD comprises six transmembrane segments
(TMSs), which are envisaged to confer substrate specificity
(Shukla et al., 2003, 2004). The NBDs of ABC-type trans-
porter proteins, on the other hand, are the sites of ATP
hydrolysis and hence the hub of energy generation to facili-
tate drug efflux. According to our current understanding,
Cdr1p and Cdr2p drug extrusion proteins not only mediate
the efflux of azoles and their derivatives but also extrude a
Abbreviations: CM, crude membranes; NBD, nucleotide-binding
domain; PM, plasma membrane; TMD, transmembrane domain; TMS,
transmembrane segment.
A supplementary figure showing the amino acid sequence alignment of
Cdr1p and Cdr3p is available with the online version of this paper.
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variety of structurally unrelated drugs and compounds
(Dogra et al., 1999; Krishnamurthy et al., 1998a; Prasad et al.,
1998; Sanglard et al., 1997; Smriti et al., 2002). However, the
molecular mechanism of drug transport mediated by Cdr1p
is not yet known.
Although analysis of the C. albicans genome reveals that it
has 28 putative ABC transporters, only CDR1 and CDR2
have been shown to be drug transporters (Braun et al., 2005;
Gaur et al., 2005). The well-characterized Cdr3p and Cdr4p,
despite having 56% and 62% identity, respectively, with
Cdr1p, and 55% and 59% identity with Cdr2p, and similar
predicted domain organization, are not involved in drug
efflux and antifungal resistance (Balan et al., 1997; Franz
et al., 1998; Sanglard et al., 1999; Smriti et al., 2002). The
non-drug transporter Cdr3p is a general phospholipid
flippase and translocates membrane phospholipids (Smriti
et al., 2002). This situation is reminiscent of the mammalian
MDR gene family, which encodes the three highly homo-
logous P-gp isoforms in mouse (mdr1,mdr2 andmdr3) and
two in humans (MDR1 andMDR2) (Ng et al., 1989). While
the overexpression of mouse mdr1 and mdr3 and human
MDR1 is closely linked to the cell’s ability to exhibit multi-
drug resistance, no such role for mouse mdr2 or human
MDR2 has been observed. Notably, MDR2, which displays
78% overall amino acid sequence identity with MDR1,
rather functions as a flippase and translocates membrane
phospholipids between two monolayers of the lipid bilayer
(Ruetz & Gros, 1994; Smit et al., 1993).
To understand the structure and function of individual
domains of drug transporter proteins, in the present study
we focused on the role and distinctiveness of the NBDs and
TMDs of Cdr1p in drug transport. For this we employed two
approaches: first we constructed chimeras between Cdr1p
and its close homologue Cdr3p and second, to study the
functional equivalence of the two cytoplasmic domains, we
constructed variants of Cdr1p molecules comprising either
the two N-terminal or two C-terminal NBDs of the same
protein. Our results demonstrate for the first time that the
N- and the C-terminal halves of Cdr1p are largely non-
exchangeable. TMS12 was the only part of Cdr1p that could
be functionally replaced with the equivalent TMS region of
the non-drug transporter Cdr3p. On the other hand, the
recombinant strain expressing a Cdr1p variant with two
N-terminal NBDs produced a chimeric protein that even
upon rescuing to the PM remained non-functional, thus
implying that the two NBDs display functional asymmetry
and non-equivalence.
METHODS
Materials. Anti-GFP monoclonal antibody was purchased from BD
Biosciences Clontech. DNA-modifying enzymes were purchased from
Roche Molecular Biochemicals. Protease inhibitors (PMSF, leupetin,
pepstatin A, aprotinin) and drugs (miconazole, ketoconazole, itracona-
zole, cycloheximide, anisomycin), rhodamine 6G and other molecular-
grade chemicals were obtained from Sigma. Ranbaxy Laboratories,
India, kindly provided fluconazole (FLC).
Media and strains. Plasmids were maintained in Escherichia coli
DH5a. E. coli was cultured in Luria–Bertani medium (Difco) to
which ampicillin was added (100 mg ml21). The bacterial and Sac-
charomyces cerevisiae strains used in this study are listed in Table 1.
The yeast strains were cultured in YEPD broth (Bio 101) or SD-
ura2 (Bio 101). For agar plates 2% (w/v) Bacto agar (Difco) was
added to the medium.
Vector construction and generation of transformants
Construction of pPS1N/3CGFP. Since plasmid pSK-PDR5PPUS
(yeast vector) has a limited choice of unique restriction enzyme
sites, initially the chimera consisting of the N-terminal half of CDR1
and the C-terminal half of CDR3 (1N/3C) was constructed in
pBluescript (pBS) by PCR amplification with a combination of pri-
mers (listed in Table 2) using either pPSCDR1GFP (Shukla et al.,
2003) or p425-GPD-CDR3* (Table 1) as template and Pwo DNA
polymerase (Roche Molecular Biochemicals) or Pfu DNA poly-
merase (Stratagene). For construction of pBS1N/3C, primers PS1
(having a XbaI restriction site) and 1NR2 were used to amplify the
N-terminal half of CDR1 using pPSCDR1GFP as template, and pri-
mers 3CF and PS4 (having a SalI restriction site) were used to
amplify the C-terminal half of CDR3 without the stop codon using
p425-GPD-CDR3* as template. The two amplicons were then ligated
and the ligated mix was used as template for the final amplification
of 1N/3C using primers PS1 and PS4. The amplified fragment was
then digested with XbaI and SalI (restriction sites introduced in the
primers) and cloned into the XbaI- and SalI-digested pBS. The
GFP ORF was amplified from pPSCDR1GFP using primers GFP-F
(having a SalI restriction site) and GFP-R (having SalI and XbaI
restriction sites). This GFP amplicon was then digested with SalI
and cloned into SalI-digested plasmid pBS1N/3C, resulting in plas-
mid pBS1N/3CGFP. The 1N/3CGFP ORF from plasmid pPBS1N/
3CGFP was then taken out with the convenient restriction site XbaI
and recloned into SpeI-digested pSK-PDR5PPUS, resulting in plas-
mid pPS1N/3CGFP.
Construction of pPS3N/1CGFP. A Similar strategy was employed
to construct the vector pPS3N/1CGFP using primers PS5 (having a
XbaI restriction site) and 3NR to amplify the N-terminal half of
CDR3, and 1CF and PS8 (having a SalI restriction site) to amplify
the C-terminal half of CDR1 without the stop codon.
Construction of pPS1(1–1173)/3(1154–1501)GFP. For construct-
ing pPS1(1–1173)/3(1154–1501)GFP vector, first the endogenous
NarI site at amino acid position 823 in pPS1N/3CGFP was modified
by site-directed mutagenesis using primers 1N/3C(NarI823)F and
1N/3C(NarI823)R and the Quickchange mutagenesis system
(Stratagene), thus resulting in pPS1N/3CGFP*. Subsequently, NarI
sites were created at amino acid positions 789 and 1173 [using primers
CDR1P(NarI789)F, CDR1P(NarI789)R and CDR1P(NarI1173)F,
CDR1P(NarI1173)R respectively] in pPSCDR1GFP, thus forming
plasmid pPSCDR1GFP3, and at amino acid positions 789 and 1165
[using primers 1N/3C(NarI789)F, 1N/3C(NarI789)R and 1N/
3C(NarI1165)F, 1N/3C(NarI1165)R respectively] in pPS1N/3CGFP*,
resulting in plasmid pPS1N/3CGFP*3 without changing the existing
codon by site-directed mutagenesis. The resulting NarI-digested
1?152 kb fragment was taken out from plasmid pPSCDR1GFP3 and
ligated to NarI-digested plasmid pPS1N/3CGFP*3.
Construction of pPS1(1–1436)/3(1420–1501)GFP. To construct
pPS1(1–1436)/3(1420–1501)GFP vector, NarI and MluI sites were
introduced at amino acid positions 789 and 1436 respectively [using
primers CDR1P(NarI789)F, CDR1P(NarI789)R and CDR1P-
(MluI1436)F, CDR1P(MluI1436)R] in pPSCDR1GFP, thus forming
plasmid pPSCDR1GFP2, and similarly, NarI and MluI sites were
introduced at amino acid positions 789 and 1431 respectively
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[using primers 1N/3C(NarI789)F, 1N/3C(NarI789)R and 1N/
3C(MluI1431)F, 1N/3C(MluI1431)R] in plasmid pPS1N/3CGFP*,
resulting in plasmid pPS1N/3CGFP*2 by site-directed mutagenesis
without changing the existing codons. The resulting NarI- and
MluI-digested 1?941 kb fragment was taken out from plasmid
pPSCDR1GFP2 and ligated to NarI- and MluI-digested plasmid
pPS1N/3CGFP*2.
Construction of pCdr1-1N/1NGFP. For constructing pCdr1-1N/
1NGFP vector, the DNA encoding a hydrophilic region including
the N-terminal NBD was amplified using pPSCDR1GFP as template
and primers CDR1F(1210) and CDR1R(2657), which allowed the
introduction of a NarI restriction site at the 59 and 39 ends of the
amplicon. The resultant amplicon was then digested with NarI-and
ligated to NarI digested pPSCDR1GFP3 vector (NarI digestion of
pPSCDR1GFP3 results in deletion of the C-terminal NBD).
Construction of pCdr1-1C/1CGFP. For constructing pCdr1-
1C/1CGFP, a HindIII restriction site was introduced at amino acid
position 494 (after the N-terminal NBD) in plasmid pPSCDR1GFP
by site-directed mutagenesis using primers HindIII 494F and
HindIII 494R, resulting in plasmid pPSCDR1GFPHindIII. The DNA
encoding a hydrophilic region including the C-terminal NBD was
amplified using pPSCDR1GFP as template and primers 1CF HindIII
Table 1. Plasmids and strains
Name Description Reference
Plasmid
pSK-PDR5PPUS Nakamura et al. (2002)
pPSCDR1GFP Carries CDR1GFP ORF Shukla et al. (2003)
p425-GPD-CDR3* Derived from p425-GPD-CDR3 (kind gift from Martine Raymond) in
which two CTG codons were converted to TCG to avoid codon
usage problem in S. cerevisiae
This study
pBS1N/3CGFP pBluescript encoding N-terminal half of CDR1 and C-terminal half of
CDR3 tagged with GFP-encoding gene at the C-terminus
This study
pBS3N/1CGFP pBluescript encoding N-terminal half of CDR3 and C-terminal half of
CDR1 tagged with GFP-encoding gene at the C-terminus
This study
pPS1N/3CGFP Carries 1N/3CGFP ORF cloned at SpeI site of pSK-PDR5PPUS This study
pPS3N/1CGFP Carries 3N/1CGFP ORF cloned at SpeI site of pSK-PDR5PPUS This study
pPS1N/3CGFP* pPS1N/3CGFP with modified NarI site in 1N/3CGFP ORF This study
pPSCDR1GFP2 pPSCDR1GFP with NarI site introduced at 789 amino acid position
and MluI site at 1436 amino acid position in CDR1GFP ORF
This study
pPS1N/3CGFP*2 pPS1N/3CGFP* withNarI site introduced at 789 amino acid position
and MluI site at 1431 amino acid position in 1N/3CGFP* ORF
This study
pPSCDR1GFP3 pPSCDR1GFP with NarI sites introduced at 789 and 1173 amino
acid position in CDR1GFP ORF
This study
pPS1N/3CGFP*3 pPS1N/3CGFP* with NarI site introduced at 789 and 1165 amino
acid position in 1N/3CGFP* ORF
This study
pPS(1-1173)/3(1154-1501)GFP pSK-PDR5PPUS encoding Cdr1p up to 1173 amino acid and Cdr3p
from amino acid 1154 to 1501, tagged with GFP-encoding gene at
the C-terminus
This study
pPS(1-1436)/3(1420-1501)GFP pSK-PDR5PPUS encoding Cdr1p up to 1436 amino acid and Cdr3p
from amino acid 1420 to 1501, tagged with GFP-encoding gene at
the C-terminus
This study
pCdr1-1N/1NGFP pPSCDR1GFP encoding two N-terminal NBDs in CDR1GFP ORF This study
pPSCDR1GFPHindIII pPSCDR1GFP with HindIII site introduced at 494 amino acid
position in CDR1GFP ORF
This study
pCdr1-1C/1CGFP pPSCDR1GFP encoding two C-terminal NBDs in CDR1GFP ORF This study
Strains
AD1-8u2 MATa pdr1-3 his1 ura3 Dyor1 : : hisG Dsnq2 : : hisG Dpdr5 : : hisG
Dpdr10 : : hisG Dpdr11 : : hisG Dycf1 : : hisG Dpdr3 : : hisG
Dpdr15 : : hisG
Nakamura et al. (2002)
PSCDR1GFP AD1-8u2 carrying CDR1GFP ORF Shukla et al. (2003)
PS1N/3CGFP AD1-8u2 carrying 1N/3CGFP ORF This study
PS3N/CGFP AD1-8u2 carrying 3N/1CGFP ORF This study
PS1(1-1173)/3(1154-1501)GFP AD1-8u2 carrying 1(1–1173)/3(1154–1501)GFP ORF This study
PS1(1-1436)/3(1420-1501)GFP AD1-8u2 carrying 1(1–1436)/3(1420–1501)GFP ORF This study
Cdr1-1N/1NGFP AD1-8u2 carrying Cdr1-1N/1NGFP ORF This study
Cdr1-1C/1CGFP AD1-8u2 carrying Cdr1-1C/1CGFP ORF This study
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Table 2. Oligonucleotides
Name Sequence (5§–3§) Purpose
GFP-F ACGCGTCGACATGAGTAAGGGAGAAGAA Forward primer with SalI site for
amplifying and cloning GFP ORF
GFP-R ACGCGTCGACGCTCTAGATTATTTGTATAGTTCATCCA Reverse primer with SalI and XbaI
site for amplifying and cloning
GFP ORF
PS1 GCTCTAGAGCGAAAAAAATTATGTCAGATTCTA Forward primer with XbaI site for
amplifying and cloning N-terminal
half of CDR1
1NR2 AGCACCTTTATTGAATTCAG Reverse primer for amplifying and
cloning N-terminal half of CDR1
3CF TCAAGTATTTCGAAAGGTGAAACT Forward primer for amplifying and
cloning CDR3 C-terminal half
PS4 CCATGTCGACAACGTTTTCATGATTGG Reverse primer with SalI site for
amplifying and cloning CDR3
C-terminal half
PS5 GCTCTAGAGCCAAAAAATGGCCAAGACATCACA Forward primer with XbaI site for
amplifying and cloning CDR3
N-terminal half
3NR TTTGTTGGTTTGAACGAAAAATA Reverse primer for amplifying and
cloning N-terminal half of CDR3
1CF ATGCAAAAGGGGGAAATTGTTTTGTTCC Forward primer for amplifying and
cloning C-terminal half of CDR1
PS8 CCATGTCGACTTTATTTCTTATTTTTTTTCTCTCTGTTACCCT Reverse primer with SalI site for
amplifying and cloning C-terminal
half of CDR1
1N/3C(NarI823)F CCTATATGGATGGTATGGCACCATTAGATTTTAGTGG Forward primer for modifying NarI
site at 823 amino acid position in
1N/3CGFP ORF
1N/3C(NarI823)R CCACTAAAATCTAATGGTGCCATACCATCCATATAGG Reverse primer for modifying NarI
site at 823 amino acid position in
1N/3CGFP ORF
1N/3C(NarI789)F CTGAATTCAATAAAGGCGCCTCAAGTATTTCGAAAGGTG Forward primer for introducing NarI
site at 789 amino acid position in
1N/3CGFP ORF
1N/3C(NarI789)R CACCTTTCGAAATACTTGAGGCGCCTTTATTGAATTCAG Reverse primer for introducing NarI
site at 789 amino acid position in
1N/3CGFP ORF
1N/3C(NarI1165)F GATACCAACCAAGCATATGCGGCGCCATTCTGGAAACAATATATC Forward primer for introducing NarI
site at 1165 amino acid position in
1N/3CGFP ORF
1N/3C(NarI1165)R GATATATTGTTTCCAGAATGGCGCCGCATATGCTTGGTTGGTATC Reverse primer for introducing NarI
site at 1165 amino acid position in
1N/3CGFP ORF
1N/3C(MluI1431)F GGTTATTTATTGAATACGCGTGCCACTGATAACTG Forward primer for introducing MluI
site at 1431 amino acid position in
1N/3CGFP ORF
1N/3C(MluI1431)R CAGTTATCAGTGGCACGCGTATTCAATAAATAACC Reverse primer for introducing MluI
site at 1431 amino acid position in
1N/3CGFP ORF
CDR1P(NarI789)F GAATTCAATAAAGGCGCCATGCAAAAGGGG Forward primer for introducing NarI
site at 789 amino acid position in
Cdr1GFP ORF
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and 1CR HindIII, which allowed the introduction of a HindIII
restriction site at the 59 and 39 ends of the amplicon. The resultant
amplicon was then digested with HindIII and ligated to HindIII-
digested pPSCDR1GFPHindIII (HindIII digestion of pPSCDR1GFP
HindIII results in deletion of the N-terminal NBD).
After every cloning, the entire chimeric construct was sequenced by
using the Big Dye Terminator Cycle sequencing kit (ABI) and an ABI
310 DNA sequencer to confirm that the construct remained in-frame
and no mutation had been introduced. Restriction enzyme digestions
further confirmed the orientation of each construct. Each plasmid,
after linearizing with XbaI, was used to transform AD1-8u2 cells as
described previously (Shukla et al., 2003). Transformation of yeast cells
was performed by the lithium acetate method using routine laboratory
protocols (Shukla et al., 2003). Single-copy integration of each trans-
formant at the PDR5 locus was confirmed by Southern hybridization
(data not shown). Two positive clones of each chimera were selected for
initial screening to rule out clonal variations.
Immunodetection of Cdr1p. Plasma membranes (PMs) were pre-
pared from S. cerevisiae as described previously (Shukla et al., 2003).
Briefly, cells were broken with glass beads. The crude membranes
(CM) were recovered by centrifugation at 1000 g to remove unbroken
cells and pelleting the CM by ultracentrifugation at 100 000 g for
1 h. The CM were then resuspended in resuspension buffer and
applied to a discontinuous gradient made of an equal volume of
53?5% (w/v) sucrose and 43?5% (w/v) sucrose. The purified PM
was recovered at the interface of the 43?5% and 53?5% sucrose
layers, following centrifugation for 5 h at 100 000 g. The Western
blot analysis was done using anti-GFP monoclonal antibody
(1 : 1000 dilution) and anti-Pma1p polyclonal antibody (1 : 10 000
dilution) as described previously (Shukla et al., 2003). Proteins on
immunoblots were visualized using the enhanced chemilumines-
cence assay system (ECL kit, Amersham Biosciences).
Confocal microscopy. The cells were grown to late exponential
phase in SD-ura2 medium, except for AD1-8u2, where uridine
(0?02%) was supplemented to the SD-ura2 medium. The cells were
then washed and resuspended in an appropriate volume of 50 mM
HEPES pH 7?0. The cells were placed on glass slides and directly
viewed with a 1006 oil-immersion objective on a confocal micro-
scope (Radiance 2100, AGR, 3Q/BLD; Bio-Rad).
Drug susceptibility and other functional parameters. The
susceptibilities of S. cerevisiae cells to different drugs were tested
CDR1P(NarI789)R CCCCTTTTGCATGGCGCCTTTATTGAATTC Reverse primer for introducing NarI
site at 789 amino acid position in
Cdr1GFP ORF
CDR1P(NarI1173)F GCACTTTTGAAATATGCGGCGCCACTTTGGAAACAATAC Forward primer for introducing NarI
site at 1173 amino acid position in
Cdr1GFP ORF
CDR1P(NarI1173)R GTATTGTTTCCAAAGTGGCGCCGCATATTTCAAAAGTGC Reverse primer for introducing NarI
site at 1173 amino acid position in
Cdr1GFP ORF
CDR1P(MluI1436)F GGTGGGTATTTTGAAACGCGTAATGATGGATCTTGTG Forward primer for introducing MluI
site at 1436 amino acid position in
Cdr1GFP ORF
CDR1P(MluI1436)R CACAAGATCCATCATTACGCGTTTCAAAATACCCACC Reverse primer for introducing MluI
site at 1436 amino acid position in
Cdr1GFP ORF
CDR1F(1210) GGCGCCATGTCAGATTCTAAGATGTCGTCG Forward primer for amplifying N-
terminal NBD of CDR1 with NarI
site
CDR1R(2657) GGCGCCGTATATGGAGATGCTGGTCTTGT Reverse primer for amplifying N-
terminal NBD of CDR1 with NarI
site
HindIII494F GTATCATTCTTTAAGCTTATGCAAGTGAGG Forward primer for introducing
HindIII site at 494 amino acid
position in Cdr1GFP ORF
HindIII494R CCTCACTTGCATAAGCTTAAAGAATGATAC Reverse primer for introducing
HindIII site at 494 amino acid
position in Cdr1GFP ORF
1CF(HindIII) GCCCAAGCTTATGCAAAAGGGGGA Forward primer for amplifying
C-terminal NBD of CDR1 with
HindIII site
1CR(HindIII) GCCCAAGCTTTGGTGCAGCATATTT Reverse primer for amplifying
C-terminal NBD of CDR1 with
HindIII site
Table 2. Oligonucleotides
Name Sequence (5§–3§) Purpose
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by microtitre plate assay and spot assay as described earlier
(Mukhopadhyay et al., 2002). The Cdr1p-associated ATPase activity
of the purified PM was measured as oligomycin-sensitive release of
inorganic phosphate as described previously (Shukla et al., 2003).
Efflux of rhodamine 6G and accumulation of [3H]fluconazole were
determined essentially as described elsewhere (Kohli et al., 2002;
Shukla et al., 2003). Approximately 107 cells from an overnight
culture were inoculated in 100 ml YPD and grown for 5–6 h at
30 uC with shaking. The cells were pelleted and washed three times
with phosphate-buffered saline (PBS) buffer without glucose. The
cells were subsequently resuspended as a 2% cell suspension in de-
energization buffer (5 mM dinitrophenol and 5 mM 2-deoxy-D-
glucose in PBS without glucose) and incubated for 2 h at 30 uC with
shaking. The cells were then washed, resuspended in PBS without
glucose and divided into four parts; rhodamine 6G was added to a
final concentration of 10 mM to each part, followed by incubation
for 2 h at 30 uC. After washing, the cells were suspended in PBS with
2% glucose. An aliquot of 1 ml was taken after 45 min and centri-
fuged at 9000 g for 2 min. The absorbance of the supernatant was
measured at 527 nm. To check the accumulation of [3H]fluconazole,
the de-energized cells were incubated with 100 nM [3H]fluconazole
(0?7 TBq mmol21) for 2 h. The cells were then washed, and sus-
pended in PBS with 2% glucose. An aliquot of 1 ml was removed
after 45 min, rapidly filtered and washed three times with ice-cold
PBS without glucose. The radioactivity that accumulated in filtered
cells and that adhered to filter disks was measured in a liquid scintil-
lation counter with a scintillation liquid (tri-Carb 2900TR; Packard).
The radioactivity that adhered to the filter disk, which was not signi-
ficant, was subtracted from the experimental values.
Photoaffinity labelling with [3H]azidopine. PM (25 mg)
protein was photoaffinity labelled with 0?5 mM [3H]azidopine
(60 Ci mmol21; 2?2 TBq mmol21) as described previously (Shukla
et al., 2003).
RESULTS
Swapping the N- and C-terminal halves of
Cdr1p and Cdr3p yields non-functional
recombinant strains
Pair-wise sequence comparisons indicate that Cdr3p dis-
plays 56% sequence identity and 74% similarity with Cdr1p
(see supplementary Fig. S1 available with the online version
of this paper). Despite the observed topological (http://
ca.expasy.org/tools/, Prasad et al., 1995; Shukla et al., 2003)
(Fig. 1A) and sequence similarity, the two proteins are
functionally distinct (Balan et al., 1997; Prasad et al., 1995;
Smriti et al., 2002). For example, we as well as others
(Sanglard et al., 1995; Prasad et al., 1995; Shukla et al., 2003)
have shown a direct involvement of Cdr1p in efflux of drugs
while Cdr3p has no such activity and is thus a non-drug
transporter (Smriti et al., 2002). Cdr3p does possess ATPase
activity but this is not coupled to drug efflux; rather it
powers translocation of phospholipids between the two
lipid monolayers of the PM. The inhibitors which block
Fig. 1. Predicted topology of Cdr1p and Cdr3p and schematic representation of CDR1/CDR3 chimeric proteins. (A)
Proposed secondary structure of Cdr1p (a) and Cdr3p (b) with two TMDs and two NBDs. (B) Illustration of the CDR1/CDR3
chimeras. The position of Cdr1p where the splice with the corresponding sequence of Cdr3p occurs is indicated. The amino
acid numbers refer to the segment of Cdr1p present in each construct.
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ATPase activity of Cdr3p also block phospholipid transloca-
tion mediated by it. Interestingly, Cdr3p appears to be
functionally oppositely oriented in the PM as compared to
Cdr1p (Smriti et al., 2002).
To determine the domain(s) of Cdr1p involved in drug
resistance, we constructed a series of CDR1/CDR3 chimeras
(Fig. 1B) by exchanging the homologous regions of CDR1
with CDR3 as described in Methods. In order to check
the localization of chimeric proteins, each construct, at the
C-terminus, was also tagged with the green fluorescent
protein (GFP). For functional analysis of the CDR1/CDR3
chimeras, a heterologous hyper-expression system, where
Cdr1p is stably overexpressed from a genomic PDR5 locus in
a S. cerevisiaemutant AD1-8u2, was used (Nakamura et al.,
2002). The host AD1-8u2, from which seven major ABC
transporters have been deleted, was derived from a Pdr1-3
mutant strain with a gain-of-function mutation in the tran-
scription factor Pdr1p, resulting in a constitutive hyper-
induction of the PDR5 promoter. The new overexpressing
strains harbouring CDR1/CDR3 chimeras were designated
PS3N/1CGFP, PS1N/3CGFP, PS1(1–1173)/3(1154–1501)-
GFP and PS1(1–1436)/3(1420–1501)GFP (see Table 1 for
details).
Interestingly, expression of proteins with homologous sub-
stitution of either the N- or the C-terminal half of Cdr1p
with Cdr3p (PS3N/1CGFP, PS1N/3CGFP) resulted in non-
functional recombinant strains. In contrast to wild-type
Cdr1p, cells expressing either of the chimeras showed no
resistance to drugs on spot and MIC80 assays (Fig. 2A, B).
This enhanced supersensitivity of recombinant strains
expressing either of the chimeras may be linked to their
poor expression and localization. To check this, we examined
the localization of wild-type Cdr1p and CDR1/CDR3GFP
chimeric proteins by confocal microscopy. The confocal
images revealed that unlike the rimmed appearance of
Cdr1pGFP in cells expressingwild-type Cdr1p, small patches
of chimeric PS3N/1CGFP protein on the cell surface were
apparent, whereas surface localization of PS1N/3CGFP
protein was more severely affected since its fluorescence
appeared trapped intracellularly (Fig. 3A). Western blot
analysis of PM proteins isolated from PS3N/1CGFP and
PS1N/3CGFP chimeras confirmed the confocal microscopy
results. None of the PM fractions isolated from these chi-
meras showed any detectable protein (Fig. 3B, a). However,
a faint band was observed with CM preparations of PS3N/
1CGFP (Fig. 3B, c). PM-ATPase was used as a marker to
check the purity of PM fraction (Fig. 3B, b).
Fig. 2. Drug-resistance profile of S. cerevisiae cells expressing wild-type Cdr1GFP and CDR1/CDR3GFP chimeric proteins
determined by the spot and MIC assays. (A) Spot assay: 5 ml samples of fivefold serial dilutions of each yeast strain (cells
suspended in a normal saline to OD600 0?1) were spotted on YEPD plates in the absence (control) or in the presence of
fluconazole (FLC; 1 mg ml”1), miconazole (MIC; 90 ng ml”1), cycloheximide (CYH; 80 ng ml”1), anisomycin (ANISO;
800 ng ml”1), ketoconazole (KTC; 125 ng ml”1), itraconazole (ITC; 100 ng ml”1) and rhodamine 6G (R6G; 6 mg ml”1). Cell
growth was monitored after 48 h incubation of plates at 30 6C. (B) MIC assay: determined following National Committee For
Clinical Laboratory Standards.
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Functional replacement of TMS12 of Cdr1p with
the homologous TMS of Cdr3p
Since swapping of theN- andC-terminal homologous halves
of Cdr1p with Cdr3p yielded non-functional recombinant
strains (Figs 2 and 3), we sequentially replaced the Cdr3p
region with Cdr1p, selecting the inactive chimera, PS1N/
3CGFP, as a framework to restore Cdr1p-like function.
Consequently, two chimeras were constructed, one com-
prising Cdr1p up to the C-terminal NBD [PS1(1–1173)/
3(1154–1501)GFP] and the other comprising Cdr1p up to
TMS11 [PS1(1–1436)/3(1420–1501)GFP]. As shown in
Fig. 2, recombinant strains expressing a chimeric protein
comprising the Cdr1p segment up to the C-terminal NBD in
PS1(1–1173)/3(1154–1501)GFP remained non-functional.
The poor functioning of the PS1(1–1173)/3(1154–1501)-
GFP chimera in the recombinant strain was apparently due
to its poor cell surface localization as was revealed by con-
focal and Western analysis (Fig. 3). These results further
emphasize the importance of the entire TMD region for the
synthesis and assembly of active protein. Interestingly, the
replacement of TMS12 of Cdr1p with the homologous TMS
of Cdr3p, as in PS1(1–1436)/3(1420–1501)GFP, resulted in
complete restoration of Cdr1p activity, which was evident
from the drug resistance profile of the recombinant strain
(Fig. 2). Thus cells expressing the PS1(1–1436)/3(1420–
1501)GFP chimera displayed increased resistance to all the
tested drugs, which was comparable to that seen with the
wild-type protein (Fig. 2).
The functionality of PS1(1–1436)/3(1420–1501)GFP was
further confirmed by analysing ATPase activity, efflux of the
fluorescent substrate rhodamine 6G and accumulation of
radiolabelled fluconazole. For this, the purified PM protein
fractions isolated from PSCDR1GFP and CDR1/CDR3GFP
chimeras were analysed for their oligomycin-sensitive
ATPase activity. Cells expressing wild-type CDR1GFP and
chimeric 1(1–1436)/3(1420–1501)GFP protein showed com-
parable oligomycin-sensitive ATPase activity, in contrast to
the rest of the chimeric proteins (Fig. 4A). In addition,
both PSCDR1GFP and PS1(1–1436)/3(1420–1501)GFP
cells showed similar levels of rhodamine 6G efflux and
fluconazole accumulation (Fig. 4B, C). As expected, con-
focal images and Western blot analysis of PS1(1–1436)/
Fig. 3. Localization and expression of wild-
type Cdr1GFP and CDR1/CDR3GFP chimeric
proteins. (A) Confocal images of AD1-8u”
and cells expressing wild-type Cdr1GFP and
CDR1/CDR3GFP chimeric proteins. (B)
Expression of wild-type Cdr1GFP and
CDR1/CDR3GFP chimeric protein in S. cer-
evisiae: PM (20 mg) proteins from AD1-8u”
(lane 1), PSCDR1GFP (lane 2), PS1N/
3CGFP (lane 3), PS3N/1CGFP (lane 4),
PS1(1–1173)/3(1154–1501)GFP (lane 5)
and PS1(1–1436)/3(1420–1501)GFP (lane
6) were separated on an 8% SDS-PAGE,
electroblotted onto a nitrocellulose mem-
brane and probed with monoclonal anti-GFP
antibody (a) and rabbit polyclonal anti-
Pma1p antibody (b). (c) CM (30 mg) pro-
teins from AD1-8u” (lane 1), PSCDR1GFP
(lane 2), PS1N/3CGFP (lane 3), PS3N/
1CGFP (lane 4), PS1(1–1173)/3(1154–
1501)GFP (lane 5) and PS1(1-1436)/
3(1420-1501)GFP (lane 6) probed with
monoclonal anti-GFP antibody. Proteins were
immunodetected by chemiluminescence using
an ECL kit (Amersham).
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3(1420–1501)GFP confirmed the proper surface localization
and expression of this chimeric protein (Fig. 3).
The N-terminal and C-terminal NBDs of Cdr1p
are non-exchangeable
One of the unresolved issues concerning the function of
Cdr1p is whether both NBDs are equivalent, and thus
interchangeable, or whether each functions only within the
context of a specific membrane environment provided by
TMDs. Our previous study has shown (Jha et al., 2003a, b,
2004) that the unique positioning of the catalytically
important residues C193 in Walker A of NBD1 and K901
in Walker A of NBD2 could not be exchanged. Hence a
construct like CDR1-1C/1NGFP was not used; instead, to
address this question, two constructs were instead made,
one having Cdr1p with cytoplasmic hydrophilic domains
comprising two N-terminal NBDs and another with two C-
terminal NBDs (Fig. 5A). These constructs were integrated
in S. cerevisiaemutant AD1-8u2 as described previously for
CDR1/CDR3 chimeras and checked for single-copy integra-
tion (data not shown). The resultant variant proteins Cdr1-
1N/1NGFP and Cdr1-1C/1CGFP were analysed for their
functionality using two independent drug sensitivity assays.
As shown in Fig. 5(B), recombinant strains expressing both
types of NBD variants were hypersensitive to all the tested
drugs as compared to those expressing wild-type CDR1GFP.
The drug sensitivities revealed by spot assay generally
matched well with the MIC80 test (data not shown).
Although both variants of NBDs were hypersensitive to the
tested drugs, confocal images revealed differences in their
surface localization. While the variant Cdr1-1N/1NGFP,
consisting of hydrophilic domains with two N-terminal
NBDs, revealed poor cell surface localization, the variant
having two C-terminal NBDs showed altogether very poor
GFP fluorescence (Fig. 5C).
The Cdr1-1N/1NGFP variant can be brought to
the cell surface by growing cells in the
presence of Cdr1p substrates
Wehad earlier observed that a non-functional TMS6mutant
variant (DF774) of Cdr1p could be functionally restored to
the cell surface if the cells were exposed to drug substrates
which act as powerful ‘chaperones’ for processing misfolded
proteins (Shukla et al., 2003). We therefore checked whether
the mislocalization of the CDR1/CDR3 chimeric proteins
and Cdr1p NBDs variants could be similarly improved. For
this, we added different drug substrates of Cdr1p separately,
immediately after the lag phase of the S. cerevisiae cells
(4–5 h). The cells were grown for a further 7 h, then checked
by confocal microscopy for the localization of the protein.
Of the two NBD variants only Cdr1-1N/1NGFP protein
showed improved surface localization with increasing con-
centrations of drugs (shown for cycloheximide in Fig. 6A,
a–f). The surface expression level of the Cdr1-1N/1NGFP
variant could be restored to that of wild-type CDR1GFP
at 50 ng cycloheximide ml21 (Fig. 6A, a–h). Interestingly,
PM protein isolated from Cdr1-1N/1NGFP cells grown in
increasing concentrations of cycloheximide also showed a
concentration-dependent increase in the amount of variant
protein in the PM fraction (Fig. 6B, a), while the presence
of drug had no effect in the cells expressing wild-type
CDR1GFP (Fig. 6A, g, h; Fig. 6B, a), thus suggesting that
there was no inhibition of protein synthesis at the con-
centration of cycloheximide used for rescue experiments.
Additionally, other substrates of Cdr1p, such as fluconazole,
Fig. 4. Functional characterization of CDR1/CDR3 GFP chi-
meras. (A) Oligomycin-sensitive ATPase activity in the PM pro-
teins of cells expressing wild-type Cdr1GFP and CDR1/CDR3
GFP chimera. ATPase activity was determined as described in
Methods. The results are the means±SD of three independent
experiments. (B, C) Comparison of rhodamine 6G efflux (B)
and fluconazole accumulation (C) in cells expressing wild-type
Cdr1GFP and CDR1/CDR3GFP. Rhodamine 6G efflux and fluco-
nazole accumulation were determined as described in Methods.
The values are the means±SD of four independent experiments.
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ketoconazole, miconazole, itraconazole and anisomycin,
were also tested to improve the localization of chimeric
proteins. Of all the substrates tested, only anisomycin could
fully rescue the Cdr1-1N/1NGFP variant protein to the PM
(Fig. 6A, k), while miconazole and itraconazole were able to
rescue the Cdr1-1N/1NGFP variant protein partially to the
PM (Fig. 6A, i, j). The presence of drugs in cells expressing
variant protein with both C-terminal NBDs (Cdr1-1C/
1CGFP) or CDR1/CDR3 chimeric proteins did not improve
localization (data not shown). It is noteworthy that no
growth difference was observed between strains harbouring
variant protein, chimeric protein and wild-type CDR1GFP
protein in the absence or presence of the concentrations of
the drugs used for the rescue experiments (data not shown).
Rescued Cdr1-1N/1NGFP protein remains
non-functional
To test whether improved localization of Cdr1-1N/1NGFP
variant protein led to the resumption of its transport
function, the efflux of rhodamine 6G was measured. The
control AD1-8u2, PSCDR1GFP and Cdr1-1N/1NGFP cells
were grown in the presence and absence of cycloheximide
(50 ng ml21) for 7–8 h, and efflux of rhodamine 6G was
assayed as described in Methods. The results depicted in
Fig. 6(C) show that rescued Cdr1-1N/1NGFP protein was
unable to mediate efflux of rhodamine 6G in the presence of
cycloheximide. In contrast to this, as observed earlier, SS6G
(DF774) cells when grown in the presence of drug showed
not only improved localization (Shukla et al., 2003) but also
restoration of rhodamine 6G efflux. These results suggest
that although Cdr1p substrates can rescue the folding defects
in one of the NBD variants Cdr1-1N/1NGFP, the protein
remains non-functional. Notably, there was some reduction
in the efflux of rhodamine 6G by wild-type CDR1GFP cells
grown in the presence of cycloheximide. The decrease in
efflux by the cells expressing wild-type Cdr1p is probably
due to the fact that cycloheximide, which is also a substrate
for the Cdr1p transporter, competes with rhodamine 6G.
Rescued Cdr1-1N/1NGFP protein is capable of
binding Cdr1p substrates but unable to
hydrolyse ATP
To address the question whether the rescued Cdr1p variant
having two identical N-terminal NBDs is non-functional
Fig. 5. Schematic representation, drug sensitivity and localization of NBD variants of Cdr1p. (A) Topological model of wild-
type Cdr1p comprising N- and C-terminal NBDs (a) and NBD variants of Cdr1p with cytoplasmic hydrophilic domains
comprising either two N-terminal NBDs (b) or two C-terminal NBDs (c). The N-terminal NBD is depicted by a filled hexagon
and C-terminal NBD by an open hexagon. (B) Drug resistance profile of wild-type and NBD variants of Cdr1GFP determined
by spot assay. Samples (5 ml) of fivefold serial dilutions of each yeast strain (cells suspended in a normal saline to OD600 0?1)
were spotted on YEPD plates in the absence (control) or in the presence of fluconazole (FLC; 1 mg ml”1), ketoconazole (KTC;
125 ng ml”1), miconazole (MIC; 90 ng ml”1), itraconazole (ITC; 100 ng ml”1), cycloheximide (CYH; 80 ng ml”1), anisomycin
(ANISO; 800 ng ml”1 and rhodamine 6G (R6G; 6 mg ml”1). Cell growth was monitored after 48 h incubation of plates at
30 6C. (C) Confocal images of S. cerevisiae cells expressing GFP-tagged Cdr1p and its NBD variants.
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because of impairment in the substrate binding or ATP
hydrolysis, we performed photoaffinity labelling with
azidopine, a dihydropyridine analogue, and also measured
ATPase activity with the PM protein fraction isolated from
the wild-type and the Cdr1p N-terminal NBDs variant
grown in the presence of cycloheximide (50 ng ml21). As
shown in Fig. 6(D), comparable azidopine labelling was
observed with PM isolated from wild-type CDR1GFP and
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Fig. 6. Properties of the Cdr1-1N/1N variant. (A) (a–f) Confocal pictures of cells expressing Cdr1-1N/1N variant grown in
the presence of increasing concentrations of cycloheximide. Cells expressing Cdr1-1N/1N variant grown without drug
substrate (a) or in the presence of the following concentrations of cycloheximide (ng ml”1): 10 (b), 20 (c), 30 (d), 40 (e), 50
(f). (g, h) PSCDR1GFP cells expressing wild-type Cdr1GFP grown in the absence and presence of 50 ng cycloheximide ml”1
respectively. (i–k) Cells expressing Cdr1-1N/1N variant grown with 50 ng ml”1 of miconazole, itraconazole and anisomycin
respectively. (B) Expression of Cdr1-1N/1N variant grown in the presence of increasing concentrations of cycloheximide. The
PM proteins from Cdr1-1N/1N variant (lane 1), Cdr1-1N/1N variant grown in the presence of increasing concentrations of
cycloheximide [10 (lane 2), 20 (lane 3), 30 (lane 4), 40 (lane 5) and 50 (lane 6) ng ml”1], and PSCDR1GFP cells grown in the
absence and presence of cycloheximide (50 ng ml”1) (lane 7 and 8 respectively), were separated on a 8% polyacrylamide
gel, electroblotted onto a nitrocellulose membrane and incubated with mouse anti-GFP monoclonal antibody (a) and rabbit
polyclonal anti-Pma1p antibody (b). Proteins were detected by chemiluminescence using an ECL kit (Amersham). (C)
Rhodamine 6G efflux from Cdr1-1N/1NGFP-expressing cells grown in the presence of cycloheximide. The rhodamine 6G
efflux by AD1-8u”, Cdr1-1N/1NGFP, SS6G (DF774) and PSCDR1GFP cells was determined as described in Methods. The
results are the means±SD of three independent experiments. (D) [3H]Azidopine labelling of AD1-8u”, Cdr1-1N/1NGFP and
PSCDR1GFP. PM protein (25 mg) was labelled with azidopine as described in Methods. (E) Oligomycin-sensitive ATPase
activity in the PM proteins of cells expressing Cdr1-1N/1NGFP and wild-type Cdr1GFP. The ATPase activity of AD1-8u”,
wild-type Cdr1GFP and Cdr1-1N/1N variant protein was determined in the PM fraction as described in Methods. The results
are the means±SD of three independent experiments.
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the Cdr1-1N/1NGFP variant. However, the Cdr1-1N/
1NGFP variant showed impaired ATPase activity as
compared to wild-type CDR1GFP (Fig. 6E).
DISCUSSION
The molecular mechanisms which govern the function of
Cdr1p or Cdr2p as efflux pumps for azoles are not well
understood, and information is needed (i) to understand
how the protein can bind a structurally diverse range of
compounds including different azoles, (ii) to define the
drug-substrate binding and (iii) to determine how ATP
binding and hydrolysis are linked to the drug transport.
In an effort to develop an understanding of the molecular
details of the drug binding and transport, we recently
overexpressed Cdr1p as a GFP-tagged fusion protein in a
heterologous hyper-expression system of S. cerevisiae and,
by employing site-directed mutagenesis, characterized drug
and nucleotide binding (Shukla et al., 2003, 2004). We
observed that several point mutations resulted in mutant
variants of Cdr1p that were hypersensitive to different drugs
(Jha et al., 2004; Shukla et al., 2003, 2004).
Our current study focused on examining the functional
relevance of the two NBDs of Cdr1p and identifying candi-
date protein segments that are important for substrate
recognition and binding. To address these questions, we
exchanged homologous segments of Cdr1p with corres-
ponding segments of the non-drug transporter Cdr3p. This
study shows that any exchange of either the N- or the C-
terminus of Cdr1p with the homologous portion of Cdr3p
results in non-functional recombinant strains (Fig. 2). It
seems that the loss of activity of CDR1/CDR3GFP chimeric
proteins could be attributed to the poor cell surface locali-
zation of these proteins (Figs 2 and 3), which could also
contribute to their enhanced degradation. These results,
however, do emphasize that although Cdr1p and Cdr3p
have great topological and sequence similarities, this resem-
blance is not symmetrically distributed between the two
halves of the proteins; positioning of both the halves of the
individual proteins is probably essential for their distinct
functions. Although the sequence identity between Cdr1p
and Cdr3p at the N-terminus and C-terminus is as high as
54% and 58%, respectively, it is distinct enough tomake the
former a drug transporter and latter a phospholipid trans-
locator (Prasad et al., 1995; Smriti et al., 2002). By employ-
ing a similar chimeric approach, Zhou et al. (1999) earlier
reported that while the N-terminal halves of human Mdr1p
andMdr2p could be switched, this degree of exchangeability
was not found between the C-terminal halves. In the present
case, unlike MDR1/MDR2 chimeras, even the replacement
of the N-terminal part of Cdr1p with the corresponding
Fig. 7. Sequence alignment and helical wheel projection of the predicted TMS12 of Cdr1p with Cdr3p. (A) Sequence
alignment of amino acid residues of Cdr1p replaced with homologous residues of Cdr3p in PS1(1–1436)/
3(1420–1501)GFP chimera. The putative TMS12 is boxed. Identical residues are linked by vertical bars. (B) The TMSs
of the amino acid sequences of Cdr1p and Cdr3p were determined with the program HMMTOP (Tusnady & Simon, 1998,
2001). The helical wheel projection of the primary amino acid sequence was constructed, using 3?6 amino acids per turn of
the helix, by the EMBOSS PEPWHEEL program (Rice et al., 2000). White letters on a black background show amino acids that
are identical between Cdr1p and Cdr3p.
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region of Cdr3p did not yield functional recombinant
strains. This implies that in spite of the high similarities
between the two homologous proteins, the TMDs of Cdr1p
and of Cdr3p cannot be exchanged.
Interestingly, replacement of residues 1437–1501 (which
include TMS12) of Cdr1p by the corresponding stretch of
Cdr3p resulted in a recombinant strain expressing a func-
tional chimeric Cdr1p variant. It would thus seem that this
extreme C-terminus probably does not contribute to the
functional difference detected between Cdr1p and Cdr3p.
We had earlier observed that the deletion of a 79 amino acid
stretch from the C-terminal end of Cdr1p, which encom-
passes TMS12 of this transporter, resulted in impaired
resistance to certain drugs (Krishnamurthy et al., 1998b).
Combining the two observations, it seems likely that TMS12
of Cdr1p does harbour drug-binding site(s), which can
be exchanged with TMS12 of Cdr3p in the PS1(1–1436)/
3(1420–1501)GFP chimeric protein. A closer look at the
TMS12 sequence of the two ABC proteins suggests that this
may be the case. Comparison of the amino acid sequence of
Cdr1p with that of Cdr3p in this residue 1437–1501 segment
revealed an overall 38% identity and the sequence identity
within TMS12 of the two proteins becomes as high as 57%
(Fig. 7A). The evident functional exchangeability of TMS12
between Cdr1p and Cdr3p provides clues about residues
present in the TM12 that may be important for substrate-
binding funtion. A site-directed mutagenesis approach
could identify such common residues between the two
homologous proteins.
Studies on various ABC transporters have revealed that ATP
hydrolysis and substrate transport are strongly dependent
on cooperation between NBD1 (N-terminal) and NBD2
(C-terminal) (Walmsley et al., 2003). Interestingly, although
NBD1 of Cdr1p contains the conserved Walker A motif
(GRPGAGCST), the commonly conserved lysine residue
within the Walker A motif is replaced by an uncommon
cysteine that appears to be a unique feature of most of the
fungal ABC transporters (Jha et al., 2004). Conversely,
NBD2 of Cdr1p contains the commonly conserved lysine
(GASGAGKT) at the equivalent position in its Walker A
motif. There is a complete lack of understanding with regard
to the functional equivalence of both the NBDs of Cdr1p
and the significance of the variation in theirWalker A amino
acid sequence (Jha et al., 2003a, b). Our more recent results
show that both the NBDs are essential for Cdr1p function,
albeit asymmetrically, and the positioning of the cysteine
and lysine residues within the respective Walker A motifs
is functionally not interchangeable (Jha et al., 2004). In
order to further probe the role of NBDs in Cdr1p, in this
study we constructed Cdr1p variants possessing either both
N-terminal NBDs or both C-terminal NBDs. Our results
show that the substitution of either NBD yielded non-
functional recombinant strains. Such a situation has pre-
viously been encountered with mammalian MDR proteins.
For example, CFTR chimeric molecules comprising either
two N-terminals or C-terminal NBDs having core NBD
sequence or the flanking sequence in addition to core NBD
were non-functional because of trafficking defects (Pollet
et al., 2000). Similarly, mouse mdr3 and human MDR1
chimeric proteins comprising two C-terminal NBDs
resulted in the synthesis of non-functional protein owing
to decreased accumulation or altered targeting of the protein
to the membrane (Beaudet & Gros, 1995; Hrycyna et al.,
1999). Of note, recently a Walker A mutation (K86M) of
an ABC half-transporter ABCG2 was shown to affect
oligomerization and surface targeting followed by retrieval
to the endoplamic reticulum (Henriksen et al., 2005).
Interestingly, in the present study, one of the NBD variants
of Cdr1p (having both N-terminal NBDs) could be rescued
to the PM if cells expressing this protein were exposed to
drug substrates. The exact mechanism by which these
specific drug substrates facilitate processing of probably
misfolded protein is not known. A possible explanation,
as suggested in case of P-gp and CFTR protein, is that the
drug-binding site(s) in the protein are formed early in the
folding intermediates during biosynthesis. It is possible that
the occupation of these drug-binding site(s) in the early
stages of folding may reduce the concentration of the
intermediate that is prone to self-aggregation, thus stabiliz-
ing the folding intermediates in a conformation that
resembles the wild-type protein, which in turn helps in
escaping the cell’s quality control mechanism (Loo&Clarke,
1997; Morello et al., 2000).
It is noteworthy that the non-functionality of rescued
N-terminal NBD variant protein was not due to any
impairment in substrate binding since [3H]azidopine label-
ling remained unaffected by this substitution of NBDs.
Therefore, the functional defect in spite of proper localiza-
tion was not due to impaired drug binding but rather to a
poor ability to hydrolyse ATP, which could be attributed
to the loss of communication between the two NBDs or
between NBDs and TMDs when exchanged. One must not
ignore the flanking sequences as well as the sequence
stretches between the Walker A, Walker B and signature C
motifs of NBDs, which if exchanged may also contribute to
the non-functionality of the variants.
The two NBDs of a number of ABC transporters have been
shown to be functionally dissimilar. Interestingly, in the case
of human P-gp, which is a close homologue of Cdr1p, the
two NBDs were partially interchangeable. For example Pgp-
1N/1N, containing two N-terminal NBDs, was functional
and was also asymmetric with respect to 8-azido-ATP
labelling, suggesting that the context of the ATP site rather
than its exact sequence is an important determinant for
ATP binding. Pgp-1C/1C and Pgp-1C/1N variants were,
however, defective in cell surface expression and function
(Hrycyna et al., 1999). In prokaryotic ABC-type transporters
such as the histidine permease of E. coli, both NBDs are
functionally identical and contribute equally to the protein’s
activity. Inactivation of either one of these NBDs in the full
protein resulted in 50% of the activity (Nikaido & Ames,
1999). On the other hand, there is clear evidence to indicate
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asymmetry of function of the NBDs of MRP1 and CFTR
(Aleksandrov et al., 2002; Gao et al., 2000).
In conclusion, our analysis of Cdr1p/Cdr3p chimeras shows
that neither the N- nor the C-terminal half of Cdr1p can be
exchanged with the homologous portion of Cdr3p. The
exchange of domains results in altered interfaces leading to
non-functional recombinant strains expressing chimeric
proteins. We have also confirmed our earlier observation
that the N- and C-terminal NBDs of Cdr1p are functionally
asymmetric. These results provide important clues to our
understanding of the complex interactions between the
NBDs and their neighbouring TMDs and should help in
resolving mechanisms of drug efflux of structurally
unrelated compounds mediated by Cdr1p.
ACKNOWLEDGEMENTS
We thank R. D. Cannon andMartine Raymond for the gifts of plasmid
and strains. We are also grateful to R. Serrano for the kind gift of
PM-ATPase antibodies and to Sneha Sudha Komath for her helpful
suggestions in preparation of the manuscript. We thank Ranbaxy
Laboratories Ltd, New Delhi, India, for providing fluconazole. The
work presented in this paper has been supported in part by grants to
R. P. from the Department of Biotechnology, India (BT/PR3825/MED/
14/488 (a)/2003), (BT/PR4862/BRB/10/360/2004) and the European
Commission, Brussels (QLK-CT-2001-02377).
REFERENCES
Aleksandrov, L., Aleksandrov, A. A., Chang, X. & Riordan, J. R.
(2002). The first nucleotide-binding domain of CFTR is a site of
stable nucleotide intercation whereas the second is a site of rapid
turnover. J Biol Chem 277, 15419–15425.
Balan, I., Alarco, A. M. & Raymond, M. (1997). The Candida albicans
CDR3 gene codes for an opaque-phase ABC transporter. J Bacteriol
179, 7210–7218.
Beaudet, L. & Gros, P. (1995). Functional dissection of P-
glycoprotein nucleotide binding domains in chimeric and mutant
proteins. J Biol Chem 270, 17159–17170.
Braun, B. R., Hoog, M. V. H., d’Enfert, C. & 40 other authors (2005).
A human curated annotation of Candida albicans genome. PLoS
Genet 1, 36–57.
Dogra, S., Krishnamurthy, S., Gupta, V., Dixit, B. L., Gupta, C. M.,
Sanglard, D. & Prasad, R. (1999). Asymmetric distribution of
phosphatidylethanolamine in C. albicans: possible mediation by
CDR1, A multidrug transporter belonging to ATP binding cassette
(ABC) superfamily. Yeast 15, 111–121.
Franz, R., Michel, S. & Morschhauser, J. (1998). A fourth gene
from the Candida albicans CDR family of ABC transporters. Gene
220, 91–98.
Gao, M., Cui, H. R., Loe, D. W., Grant, C. E., Almquist, K. C., Cole,
S. P. C. & Deeley, R. G. (2000). Comparison of the functional
characteristics of the nucleotide binding domains of the multidrug
resistance protein 1. J Biol Chem 275, 13098–13108.
Gaur, M., Devapriya, C. & Prasad, R. (2005). The complete inventory
of ABC proteins in human pathogenic yeast, Candida albicans. J Mol
Microbiol Biotechnol 9, 3–15.
Henriksen, U., Gether, U. & Litman, T. (2005). Effect of Walker A
mutation (K86M) on oligomerization and surface targeting of the
multidrug resistance transporter ABCG2. J Cell Sci 118, 1417–1426.
Hrycyna, C. A., Ramachandra, M., Germann, U. A., Cheng, P., Wu,
Pastan, I. & Gottesman, M. M. (1999). Both ATP sites of human
P-glycoprotein are essential but not symmetric. Biochemistry 38,
13887–13899.
Jha, S., Karnani, N., Dhar, S. K., Mukhopadhyay, K., Shukla, S.,
Saini, P., Mukhopadhyay, G. & Prasad, R. (2003a). Purification and
charaterization of N-terminal nucleotide binding domain of an ABC
drug transporter ofCandida albicans: uncommon cysteine 193 ofWalker
A is critical for ATP hydrolysis. Biochemistry 42, 10822–10832.
Jha, S., Karnani, N., Lynn, A. M. & Prasad, R. (2003b). Covalent
modification of cysteine 193 impairs ATPase function of nucleotide-
binding domain of a Candida drug efflux pump. Biochem Biophys
Res Commun 310, 869–875.
Jha, S., Dabas, N., Karnani, N., Saini, P. & Prasad, R. (2004). ABC
multidrug transporter Cdr1p of Candida albicans has divergent
nucleotide-binding domains which display functional asymmetry.
FEMS Yeast Res 5, 63–72.
Kohli, A., Smriti, Mukhopadhyay, K., Rattan, A. & Prasad, R.
(2002). In vitro low-level resistance to azoles in Candida albicans is
associated with changes in membrane lipid fluidity and asymmetry.
Antimicrob Agents Chemother 46, 1046–1052.
Krishnamurthy, S., Gupta, V., Snehlata, P. & Prasad, R. (1998a).
Characterisation of human steroid hormone transport mediated by
Cdr1p, multidrug transporter of Candida albicans, belonging to the
ATP binding cassette super family. FEMS Microbiol Lett 158, 69–74.
Krishnamurthy, S., Chatterjee, U., Gupta, V., Prasad, R., Das, P.,
Snehlata, P., Hasnain, S. E. & Prasad, R. (1998b). Deletion of
transmembrane domain 12 of CDR1, a multidrug transporter from
Candida albicans, leads to altered drug specificity: expression of a
yeast multidrug transporter in Baculovirus expression system. Yeast
14, 535–550.
Loo, T. W. & Clarke, D. M. (1997). Correction of defective protein
kinesis of human P-glycoprotein mutants by substrates and
modulators. J Biol Chem 272, 709–712.
Morello, J.-P., Petaja-Repo, U. E., Bichet, D. G. & Bouvier, M. (2000).
Pharmacological chaperones: a new twist on receptor folding. Trends
Pharmacol Sci 21, 466–468.
Mukhopadhyay, K., Kohli, A. K. & Prasad, R. (2002). Drug suscepti-
bilities of yeast cells are affected by membrane lipid composition.
Antimicrob Agents Chemother 46, 3695–3705.
Nakamura, K., Niimi, M., Niimi, K., Holmes, A. R., Yates, J. E.,
Decottignies, A., Monk, B. C., Goffeau, A. & Cannon, R. D. (2002).
Functional expression of Candida albicans drug efflux pump Cdr1p
in a Saccharomyces cerevisiae strain deficient in membrane trans-
porters. Antimicrob Agents Chemother 45, 3366–3374.
Ng, W. F., Sarangi, F., Zastawny, R. L., Veinot-Drebot, L. & Ling, V.
(1989). Identification of members of the P-glycoprotein multigene
family. Mol Cell Biol 9, 1224–1232.
Nikaido, K. & Ames, G. F. L. (1999). One intact ATP-binding subunit
is sufficient to support ATP hydrolysis and translocation in an ABC
transporter, the histidine permease. J Biol Chem 274, 26727–26735.
Pollet, J.-F., Geffel, J. V., Stevens, E. V., Geffel, R. V., Beauwens, R.,
Bollen, A. & Jacobs, P. (2000). Expression and intracellular pro-
cessing of chimeric and mutant CFTR molecules. Biochim Biophys
Acta 1500, 59–69.
Prasad, R., Worgifosse, P. D., Goffeau, A. & Balzi, E. (1995).
Molecular cloning and characterisation of a novel gene of C. albicans,
CDR1, conferring multiple resistance to drugs and antifungals. Curr
Genet 27, 320–329.
1572 Microbiology 152
P. Saini, N. A. Gaur and R. Prasad
Prasad, R., Krishnamurthy, S., Gupta, V. & Panwar, S. L. (1998).
Multidrug transporters of Candida albicans. Folia Microbiol 43, 228.
Rice, P., Longden, I. & Bleasby, A. (2000). EMBOSS: the European
Molecular Biology Open Software Suite. Trends Genet 16, 276–277.
Ruetz, S. & Gros, P. (1994). Phosphatidylcholine translocase: a
physiological role for the mdr2 gene. Cell 77, 1071–1081.
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J.-L., Monod, M. &
Bille, J. (1995). Mechanisms of resistance to azole antifungal agents
in Candida albicans isolates from AIDS patients involve specific
multidrug transporters. Antimicrob Agents Chemother 39, 2378–2386.
Sanglard, D., Ischer, F., Monod, M. & Bille, J. (1997). Cloning of
Candida albicans genes conferring resistance to azole antifungal
agents: characterization of CDR2, a new multidrug ABC transporter
gene. Microbiology 143, 405–416.
Sanglard, D., Ischer, F., Monod, M., Dogra, S., Prasad, R. & Bille, J.
(1999). Analysis of the ATP-binding cassette (ABC)-transporter gene
CDR4 from Candida albicans. In ASM Conference on Candida and
Candidiasis, Charleston, SC, USA, March 1–4, p. 56.
Shukla, S., Saini, P., Smriti, Jha, S., Ambudkar, S. V. & Prasad, R.
(2003). Functional characterization of Candida albicans ABC
transporter Cdr1p. Eukaryot Cell 2, 1361–1375.
Shukla, S., Ambudkar, S. V. & Prasad, R. (2004). Substitution of
threonine-1351 in the multidrug transporter Cdr1p of Candida
albicans results in hypersusceptibility to antifungal agents and
threonine-1351 is essential for synergic effects of calcineurin
inhibitor FK520. J Antimicrob Chemother 54, 38–45.
Smit, J. J., Schinkel, A. H., Oude Elferink, R. P. J. & 11 other authors
(1993). Homozygous disruption of the murine mdr2 P-glycoprotein
gene leads to complete absence of phospholipid from bile and to
liver disease. Cell 75, 451–462.
Smriti, Krishnamurthy, S., Dixit, B. L., Gupta, C. M., Milewski, S. &
Prasad, R. (2002). ABC transporters Cdr1p, Cdr2p and Cdr3p of a
human pathogen Candida albicans are general phospholipid
translocators. Yeast 19, 303–318.
Tusnady, G. E. & Simon, I. (1998). Principles governing amino acid
composition of integral membrane proteins: applications to topology
prediction. J Mol Biol 283, 489–506.
Tusnady, G. E. & Simon, I. (2001). The HMMTOP transmembrane
topology prediction server. Bioinformatics 17, 849–850.
Walmsley, M. B., Mckeegan, K. S. & Walmsley, A. R. (2003).
Structure and function in efflux pumps that confer resistance to
drugs. Biochem J 376, 313–338.
White, T. C., Marr, K. A. & Bowden, R. A. (1998). Clinical, cellular,
and molecular factors that contribute to antifungal drug resistance.
Clin Microbiol Rev 11, 382–402.
Zhou, Y., Gottesman, M. M. & Pastan, I. (1999). Domain
exchangeability between the multidrug transporter (MDR1) and
phosphatidylcholine flippase (MDR2). Mol Pharmacol 56, 997–1004.
http://mic.sgmjournals.org 1573
Functional analysis of Cdr1p chimeras
